Etretinate is a synthetic aromatic retinoid.
The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases.
In dogs, this drug may be of assistance with clinical resolution of symptoms associated with follicular dysplasia, sebaceous adenitis and seborrhea, as well as for treatment of cutaneous lymphoma.
- White SD et al (1995) Sebaceous adenitis in dogs and results of treatment with isotretinoin and etretinate: 30 cases (1990-1994). J Am Vet Med Assoc 207(2):197-200
- Scott DW & Miller WH (1996) Primary seborrhoea in English springer spaniels: a retrospective study of 14 cases. J Small Anim Pract 37(4):173-178
- White SD et al (1993) Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc 202(3):387-391